TAFI (Thrombin Activatable Fibrinolysis Inhibitor) as a Marker of Hemostatic Alteration in Patients with -Thalassemia
Hany Shawky Mortagy;
Abstract
Beta-thalassemia is a hereditary hemolytic anemia with varying degrees of severity. Severely affected patients are treated with blood transfusion to maintain optimum level of hemoglobin for normal growth and physical activities. Splenectomy is indicated i
Other data
| Title | TAFI (Thrombin Activatable Fibrinolysis Inhibitor) as a Marker of Hemostatic Alteration in Patients with -Thalassemia | Authors | Hany Shawky Mortagy | Keywords | TAFI (Thrombin Activatable Fibrinolysis Inhibitor) as a Marker of Hemostatic Alteration in Patients with -Thalassemia | Issue Date | 2008 | Description | Beta-thalassemia is a hereditary hemolytic anemia with varying degrees of severity. Severely affected patients are treated with blood transfusion to maintain optimum level of hemoglobin for normal growth and physical activities. Splenectomy is indicated i |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.